Takeda Pharmaceutical Co ADR (NYSE: TAK) has a price-to-earnings ratio that is above its average at 33.46x. The stock has a 36-month beta value of 0.59. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TAK is 3.14B, and at present, short sellers hold a 0.26% of that float. On April 24, 2024, the average trading volume of TAK was 1.86M shares.
TAK) stock’s latest price update
Takeda Pharmaceutical Co ADR (NYSE: TAK)’s stock price has gone rise by 0.15 in comparison to its previous close of 13.36, however, the company has experienced a 1.13% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-03-25 that M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma’s balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
TAK’s Market Performance
TAK’s stock has risen by 1.13% in the past week, with a monthly drop of -7.15% and a quarterly drop of -9.16%. The volatility ratio for the week is 0.74% while the volatility levels for the last 30 days are 0.98% for Takeda Pharmaceutical Co ADR. The simple moving average for the past 20 days is -1.48% for TAK’s stock, with a -8.50% simple moving average for the past 200 days.
Analysts’ Opinion of TAK
Many brokerage firms have already submitted their reports for TAK stocks, with BofA Securities repeating the rating for TAK by listing it as a “Buy.” The predicted price for TAK in the upcoming period, according to BofA Securities is $20 based on the research report published on March 16, 2023 of the previous year 2023.
Cowen, on the other hand, stated in their research note that they expect to see TAK reach a price target of $24, previously predicting the price at $21. The rating they have provided for TAK stocks is “Outperform” according to the report published on July 19th, 2022.
TAK Trading at -5.51% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.82% of loss for the given period.
Volatility was left at 0.98%, however, over the last 30 days, the volatility rate increased by 0.74%, as shares sank -5.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.04% lower at present.
During the last 5 trading sessions, TAK rose by +1.13%, which changed the moving average for the period of 200-days by -13.57% in comparison to the 20-day moving average, which settled at $13.54. In addition, Takeda Pharmaceutical Co ADR saw -6.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TAK starting from TAKEDA PHARMACEUTICAL CO LTD, who sale 3,703,703 shares at the price of $8.10 back on Jan 24 ’24. After this action, TAKEDA PHARMACEUTICAL CO LTD now owns 3,755,583 shares of Takeda Pharmaceutical Co ADR, valued at $29,999,994 using the latest closing price.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.68 for the gross margin
The net margin for Takeda Pharmaceutical Co ADR stands at 0.04. The total capital return value is set at 0.03. Equity return is now at value 2.68, with 1.25 for asset returns.
Based on Takeda Pharmaceutical Co ADR (TAK), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.16. The debt to equity ratio resting at 0.69. The interest coverage ratio of the stock is 1.45.
Currently, EBITDA for the company is 1.21 trillion with net debt to EBITDA at 3.89. When we switch over and look at the enterprise to sales, we see a ratio of 2.61. The receivables turnover for the company is 5.61for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.06.
Conclusion
To sum up, Takeda Pharmaceutical Co ADR (TAK) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
